Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday.
That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone.
The price of the new shares would depend on the firm’s average share price over the five days before the secondary offering, Chang said. Companies usually offer discounts of up to 30 percent, she said.
As Senhwa Biosciences shares have stayed above NT$100 in the past few months, the company expects to raise at least NT$1.5 billion from the issuance of 15 million new shares, Chang said.
The fresh funds would fuel the company’s research and development of Silmitasertib, or CX-4945, which is a small-molecule drug for cancers, such as bile duct cancer, but has shown potential to combat the novel coronavirus with its capability to curb replication of the ribonucleic acid virus.
The company plans to test the drug on mice to evaluate its efficacy in cooperation with the US National Institutes of Health (NIH) next month, Senhwa Biosciences chief executive officer Soong Tai-sen (宋台生) said by telephone yesterday.
The preparation of the animal tests would take some time, as the mice first need to be genetically engineered to have a human version of a protein known as the angiotensin-converting enzyme 2 receptor, which the coronavirus uses as its point of entry, Soong said.
He expects the animal tests to be completed by the end of next month.
As conducting human tests with the experimental drug would be expensive, with an average cost of US$80,000 per subject, Senhwa Biosciences plans to apply to foreign agencies, such as the US Biomedical Advanced Research and Development Authority, for sponsorship, Soong said.
“Although the development of vaccines against COVID-19 is eye-catching, I think drugs will be the real solution for the pandemic, as COVID-19 antibodies might fade in less than two months, according to recent studies,” Soong said.
Senhwa Biosciences shares advanced 9.96 percent to NT$139.5 in Taipei trading yesterday, after an international team led by researchers at the University of California, San Francisco, identified Silmitasertib as one of the several drugs that could disrupt the viral takeover of cells.
The company’s shares have risen 120 percent from NT$63.5 in March, when the company began focusing on exploiting the experimental drug to treat COVID-19.
END TO SPECULATION: The hotel’s management contract has been extended, despite reports that it wanted to end its alliance with Hyatt Hotels over a deal with Riant Capital Singapore-based Hong Leong Hotel Development Ltd (豐隆大飯店股份) yesterday said it has extended a management contract to ensure the continued presence of the Grand Hyatt brand in Taipei, ending rumors that the two sides were parting ways. “We are pleased Hyatt is able to come to terms on the extension of the management contract of Grand Hyatt Taipei,” said Kwek Leng Beng (郭令明), executive chairman of City Developments Ltd (城市發展) and Millennium & Copthorne Hotels Ltd (千禧國敦酒店). Hong Leong Hotel Development is a subsidiary of Millennium, and both fall under the Hong Leong Group (豐隆集團). The Grand Hyatt Taipei (台北君悅大飯店), owned and built by
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
Nintendo Co is raising its target for Switch production to about 25 million units this fiscal year, people familiar with the matter said, as the ongoing COVID-19 pandemic keeps lifting demand and component shortages ease. The Kyoto, Japan-based company, which in April hiked orders to 22 million units by March next year, is asking partners to tack on another few million units, said the people, who did not want to be identified discussing internal goals. Assembly partners plan to work at maximum capacity through December. The new production target suggests that Nintendo is likely to outperform its Switch sales forecast of 19 million
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US